Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 8/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 2/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4058598 | 0.86 | PRMT5 (0.47) | AURKAPRMT5PDE5APDE4APDE4B | |
| SCHEMBL4060141 | 0.85 | LMNA (0.46) | AURKASMN1; SMN2LMNAHTTNPSR1 | |
| SCHEMBL13607835 | 0.83 | HDAC6 (0.38) | IGF1R | |
| SCHEMBL4054555 | 0.82 | AURKA (0.67) | AURKASMN1; SMN2LMNAHTTNPSR1 | |
| SCHEMBL4051426 | 0.82 | AURKA (0.42) | AURKAPRMT5PDE5APDE4APDE4B | |
| SCHEMBL4050654 | 0.81 | AURKA (0.52) | AURKASMN1; SMN2LMNAHTTNPSR1 | |
| SCHEMBL4051896 | 0.81 | SCD (0.47) | AURKAPRMT5PDE5APDE4APDE4B | |
| SCHEMBL4058201 | 0.80 | SMN1; SMN2 (0.55) | AURKASMN1; SMN2LMNAHTTNPSR1 | |
| SCHEMBL4059124 | 0.79 | AURKA (0.53) | AURKASMN1; SMN2LMNAHTTNPSR1 | |
| SCHEMBL4055350 | 0.78 | SMN1; SMN2 (0.53) | AURKASMN1; SMN2LMNAHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | AURKA 247/4885SMN1; SMN2 4289/4885LMNA 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.